F2G

F2G is a clinical-stage biotech with a 20+ year history, pioneering a novel approach to antifungal therapy. The company is developing a first-in-class agent targeting rare, life-threatening fungal infections, an area with significant unmet need and growing global health concern. With a seasoned leadership team experienced in drug development and commercialization, F2G is advancing its lead candidate through clinical trials. The company operates as a private entity, positioning itself to address a challenging and high-priority infectious disease market.

Functional fungal genomics platform targeting novel pathways, specifically dihydroorotate dehydrogenase (DHODH), for a first-in-class mechanism of action against fungal pathogens.

F2G competes with established antifungal classes (azoles, echinocandins) and generic amphotericin B. Its primary differentiation is its novel mechanism targeting resistant molds. It also faces potential competition from other companies developing new antifungal classes, though the field is less crowded than in antibiotics.